🇺🇸 FDA

Intelligence Platform

Patents

Browse 2,828 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10172844

Use of CDK9 inhibitors to reduce cartilage degradation

The Regents of the University of California · Granted Tue Jan 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10167292

Benzodiazepines as bromodomain inhibitors

Catalyst Therapeutics Pty Ltd. · Granted Tue Jan 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10166216

Substituted triazoles useful as Axl inhibitors

Rigel Pharmaceuticals, Inc. · Granted Tue Jan 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10167259

Allosteric inhibitors of proteasome and methods of use thereof

The Board of Regents of the University of Texas System · Granted Tue Jan 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10160753

Indazole compounds as IRAK4 inhibitors

Aurigene Discovery Technologies Limited · Granted Tue Dec 25 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10160760

Compounds useful as inhibitors of ATR kinase

Vertex Pharmaceuticals Incorporated · Granted Tue Dec 25 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10155789

Substrates and inhibitors of prolyl oligopeptidase and methods of use thereof

The Board of Regents of the University of Oklahoma · Granted Tue Dec 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10150783

Heterocyclic ITK inhibitors for treating inflammation and cancer

Aclaris Therapeutics, Inc. · Granted Tue Dec 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10151756

Predictive markers for polyamine inhibitor cancer therapies

Arizona Board of Regents on Behalf of the University of Arizona · Granted Tue Dec 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10144930

Inhibitors of MYH7B and uses thereof

MIRAGEN THERAPEUTICS, INC. · Granted Tue Dec 04 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10138486

Inhibitors of DEK protein and related methods

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Nov 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10137121

Methods of treating cancer with farnesyltransferase inhibitors

Kura Oncology, Inc. · Granted Tue Nov 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10138255

Piperazine derivatives as HIV protease inhibitors

MSD R&D (China) Co. Ltd. · Granted Tue Nov 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10137100

Administration of serine protease inhibitors to the stomach

The Regents of the University of California · Granted Tue Nov 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10132810

Method for assessing and predicting efficacy of breast cancer treatment with a long-acting

Nektar Therapeutics · Granted Tue Nov 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10130618

Pharmaceutical combinations of dabigatran and proton pump inhibitors

SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI · Granted Tue Nov 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10130623

Tyrosine kinase inhibitors

Rigel Pharmaceuticals, Inc. · Granted Tue Nov 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10131659

Iodonium analogs as inhibitors of NADPH oxidases and other flavin dehydrogenases; formulat

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Nov 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10130642

Neprilysin inhibitors

Theravance Biopharma R&D IP, LLC · Granted Tue Nov 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10125134

KRas G12C inhibitors

Mirati Therapeutics, Inc. · Granted Tue Nov 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10125128

GLS1 inhibitors for treating disease

The Board of Regents of the University of Texas System · Granted Tue Nov 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10125131

Selective HDAC3 inhibitors

Regenacy Pharmaceuticals, Inc. · Granted Tue Nov 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10123984

Neprilysin inhibitors

Theravance Biopharma R&D IP, LLC · Granted Tue Nov 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10125102

Human plasma kallikrein inhibitors

BioCryst Pharmaceuticals, Inc. · Granted Tue Nov 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted